Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series

Arthritis Care and Research

Volumn 63, Issue 5, 2011, Pages 761-765

  Kermani, Tanaz A ^a   Ytterberg, Steven R ^a   Warrington, Kenneth J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PREDNISONE;

AGED; ARTICLE; ARTIFICIAL VENTILATION; BIOPSY; CLINICAL ARTICLE; DISEASE CLASSIFICATION; FEMALE; GIANT CELL ARTERITIS; HUMAN; INTENSIVE CARE UNIT; LUNG LAVAGE; MALE; MEDICAL RECORD REVIEW; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; SMEAR; TERTIARY HEALTH CARE;

AGED; AGED, 80 AND OVER; BIOPSY; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; INTENSIVE CARE; LENGTH OF STAY; MALE; MINNESOTA; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; PREDNISONE; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; RISK FACTORS; SPUTUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958831889     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20435     Document Type: Article

References (19)

1. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703-8. (Pubitemid 37296477)
2. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-98.
3. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996;71:5-13. (Pubitemid 26021784)
4. Crayton HE, Sundstrom WR. Pneumocystis carinii pneumonia following corticosteroid therapy for giant cell arteritis. Wis Med J 1991;90:170-1.
5. Krebs S, Gibbons RB. Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia. Mil Med 1996;161:58-60. (Pubitemid 26035355)
6. Hedderwick SA, Bonilla HF, Bradley SF, Kauffman CA. Opportunistic infections in patients with temporal arteritis treated with corticosteroids. J Am Geriatr Soc 1997;45:334-7. (Pubitemid 27114307)
7. Sendi P, Wolf A, Graber P, Zimmerli W. Multiple opportunistic infections after high-dose steroid therapy for giant cell arteritis in a patient previously treated with a purine analog. Scand J Infect Dis 2006;38:922-4. (Pubitemid 44489524)
8. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8. (Pubitemid 20273297)
9. Moosig F, Holle JU, Gross WL. Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res Ther 2009;11:253.
10. Kermani TA, Schafer VS, Crowson CS, Hunder GG, Gabriel SE, Matteson EL, et al. Increase in age at onset of giant cell arteritis: a population-based study [letter]. Ann Rheum Dis 2010;69:780-1.
11. Ognibene FP, Shelhamer JH, Hoffman GS, Kerr GS, Reda D, Fauci AS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995; 151:795-9.
12. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98. (Pubitemid 28016415)
13. Godeau B, Mainardi JL, Roudot-Thoraval F, Hachulla E, Guillevin L, Huong Du LT, et al. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis 1995;54:991-4.
14. Arend SM, Kroon FP, van't Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993: an analysis of 78 cases. Arch Intern Med 1995;155:2436-41.
15. Monnet X, Vidal-Petiot E, Osman D, Hamzaoui O, Durrbach A, Goujard C, et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV. Crit Care 2008;12:R28.
16. Enomoto T, Azuma A, Kohno A, Kaneko K, Saito H, Kametaka M, et al. Differences in the clinical characteristics of Pneumocystis jiroveci pneumonia in immunocompromized patients with and without HIV infection. Respirology 2010;15:126-31.
17. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999; 42:780-9. (Pubitemid 29172000)
18. Cettomai D, Gelber AC, Christopher-Stine L. A survey of rheumatologists' practice for prescribing Pneumocystis prophylaxis. J Rheumatol 2010;37:792-9.
19. Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 2000;43:1841-8.